Kornimate/medical-research-clean huggingface dataset:
genetic registry for rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: many genes are thought to contribute to rheumatoid arthritis (ra). this study will attempt to identify genes that may contribute to ra.

the identification of genes for complex disorders such as ra requires large numbers of genetically informative families. this study enrolls people diagnosed with with ra and their families. this study will enroll 1000 ra patients and their parents. participants with ra will be evaluated at his or her doctor's office or other location convenient for the participant. participants will have a brief phone interview with a study coordinator and a blood sample will be obtained. disease evaluation will be done at one visit and will include confirmation of diagnosis, a 28 joint count, joint alignment and mobility score (jams) and administration of a health assessment questionnaire.

Eligibility criteria:
inclusion criteria: * adult onset ra * diagnosis of ra made between 18 and 60 years old * both parents alive and willing to participate * parents may have diagnosis of ra (affected) or be unaffected exclusion criteria: * inflammatory bowel disease * lupus * psoriatic arthritis

Keywords: genetics
the natural history and biological study of pulmonary recurrent respiratory papillomatosis (prrp)

Conditions: Recurrent Respiratory Papillomatosis; Pulmonary Neoplasm

Summary: recurrent respiratory papillomatosis (rrp) is an orphan disease that affects approximately 20,000 people in the united states and is caused by infection with human papillomavirus (hpv) types 6 and 11. since rrp is an orphan disease, it is an understudied disease entity with correspondingly few treatment options. the investigators hypothesize that by understanding the biology of rrp and the failed host immune responses against hpv, novel and rational therapies can be developed. this study will examine the genetic and immunologic alterations found in these rare tumors and distant metastatic involved sites (such as the lung) in patients diagnosed with rrp.

since rrp is an orphan disease, any single institution or hospital treats a limited number of rrp patients. the primary purpose for establishing a tissue repository is to collect rrp tissue from various institutions and hospitals and to provide investigators access to a large number of rrp tissues to perform genetic and immunologic studies of these rare tumors. this is both a prospective and retrospective tissue collection repository. tissue that will be collected will include excess fresh or archived human tissue, either normal or pathological, that was removed as part of standard of care clinical procedures and/or during procedures performed for separate research purposes, such as a therapeutic clinical trial. prospectively collected and archived pathology samples will be obtained under informed consent from those patients who are still living. the tissue repository will be de-identified. the pi and the rrp foundation will collaborate and serve as the gatekeepers of the repository and oversee any tissue requests. any academic collaborator(s) or for-profit collaborator(s) can request access to the tissue specimens. the investigator or collaborators should submit a letter to express interest in obtaining tissue from the tissue repository to the rrp foundation and the pi.

Eligibility criteria:
inclusion criteria: * history of hpv-associated recurrent respiratory papillomatosis * has pulmonary lesions exclusion criteria: * none
arthroscopic repair versus high tibial osteotomy for medial meniscus posterior root tears

Conditions: Medial Mensical Tear

Summary: the goal of the trial is to compare arthroscopic repair against opening wedge high tibial osteotomy for medial meniscus posterior root tears

all patients included in this clinical trial will be informed by written consent will undergo a one week screening to determine the eligibility for study entry. patients who meet the eligibility requirements will be randomized in a single blinded manner (patients).

Eligibility criteria:
inclusion criteria: * sex: both sexes. * age: above 40 * degree of varus: neutral to 10 degrees of varus exclusion criteria: * history of high energy trauma. * multiligamentous knee injury.

Keywords: medial meniscus posterior root tear high tibial osteotomy arthroscopic root repair transtibial pullout arthroscopic repair open wedge
tele-rehabilitation for cognitive disorders

Conditions: Rehabilitation; Stroke; Telerehabilitation; Telemedicine

Summary: the aim of the study is to evaluate whether a computer-based cognitive treatment delivered via tele-rehabilitation produces an improvement in cognitive functioning comparable to the improvement achievable through the same treatment delivered in person in patients with stroke outcomes. to investigate, using a custom-designed questionnaire, the feasibility and patient satisfaction with the rehabilitative treatment delivered via telemedicine compared to the same treatment delivered in person.


Eligibility criteria:
inclusion criteria: * diagnosis of ischemic or hemorrhagic stroke; * age between 18 and 90 years; * first stroke event; * stroke occurred more than 30 days ago; * adequate level of understanding; * presence of one or more of the following cognitive disorders: * memory disorders * attention disorders * executive function disorders * availability of an internet connection at the patient's home necessary for the telemedicine procedures. exclusion criteria: * presence of other neurological disorders; * presence of pre-morbid cognitive decline; * psychiatric disorders in the medical history; * alcohol and/or drug abuse; * presence of severe uncorrected visual deficits.

Keywords: stroke telemedicine rehabilitation
a prospective, randomized study of operative and nonoperative treatment for primary traumatic patellar dislocation

Conditions: Patellar Dislocation

Summary: the objective of this prospective, randomized cohort study was to evaluate the clinical results between operative and nonoperative treatment of primary patellar dislocation.

there is no consensus about management of acute traumatic primary patellar dislocations in young physically active adults. acute lateral patellar dislocation is a relatively common injury among young adults. proper treatment for this condition has been researched for decades. however, there is a lack of prospective randomized studies to evaluate the different treatment options for traumatic primary patellar dislocations. therefore a prospective, randomized study was designed with the aim to compare the outcome of operative versus nonoperative treatment of primary traumatic patellar dislocations in young adults.

Eligibility criteria:
inclusion criteria: * an acute primary traumatic patellar dislocation exclusion criteria: * previous dislocation or subluxation of the patella * pre-existing ipsilateral or contralateral knee pathology * previous knee trauma or patellar fracture.
the effect of intravitreal erythropoietin injection for refractive diabetic macular edema

Conditions: Refractory Diabetic Macular Edema

Summary: after advent of rd photoreceptor degeneration occurred. this process appears as a incredible and progressive event that will not stop till reattachment of rpe and neurosensory retina happened . process of degeneration begins from first hours of rd establishment neuroprotection of photoreceptor following rd is a novel and debatable discussion encountered in recent years . how to stop this phenomena and neuroprotective agent role in this issue are a new interest of researches. in the study investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study.


Eligibility criteria:
inclusion criteria: * patient with refractory diabetic macular edema at least one month after third injection exclusion criteria: * previous vitreoretinal surgery previous glaucoma surgery glaucomatous patient open heart surgery active proliferative diabetic retinopathy one eye patients vitreous hemorrhage
fructose: substrate, stimulus, or both?

Conditions: Insulin Resistance; Insulin Sensitivity; Pre Diabetes

Summary: this objective of this study is to use sensitive methodology under controlled conditions to investigate the mechanisms by which fructose consumption contributes to excess fatty acid synthesis and elevations in blood glucose levels following consumption of meals containing fructose.


Eligibility criteria:
inclusion criteria: * body mass index 22 to 35 kg/m2 * prediabetic (hba1c 5.7% to 6.5%) or hyperinsulinemic (fasting insulin ≥12 µiu/ml) but non-diabetic (fasting glucose \<126mg/dl and hba1c \< 6.5%) ; or normal control (fasting insulin \<10 µiu/ml, fasting glucose \<100 mg/dl, and hba1c \< 5.7%) exclusion criteria: * pregnancy or lactation within the past six months * type 1 or 2 diabetes mellitus * history of liver disease or aspartate aminotransferase (ast) and alanine aminotransferase (alt) 2x the upper limit of normal (uln); * fasting triglyceride or total cholesterol levels above 95th percentile for age and sex; * hemoglobin or hematocrit below the lower limit of normal for sex; * report of hepatitis or hiv infection; * history of cancer, use of any anti-diabetic medications or hypolipidemic agents in the past six months; * history of surgical procedure for obesity; * self-reported change in body weight \>5% in the past six months; * history of other conditions known to affect insulin sensitivity and lipid metabolism; * known intolerance to acetaminophen or components of the liquid test meals.

Keywords: fructose glucose lipogenesis
safety study of cervical sympathetic block for cerebral vasospasm following aneurysmal subarachnoid hemorrhage

Conditions: Vasospasm

Summary: to evaluate the feasibility of performing a cervical sympathetic block in patients with severe cerebral vasospasm involving the anterior cerebral circulation following aneurysmal sah.


Eligibility criteria:
inclusion criteria: 1. high grade spontaneous sah (fisher grade iii and iv) 2. secured aneurysm (clipped/coiled) 3. evidence of severe vasospasm - mca mean flow velocity \>200 cm/sec and lindegaard ratio \>6 or symptomatic vasospasm with either angiographic evidence (no angioplasty), or at least moderate severity according to tcd criteria (mca mean flow velocity \>150 cm/sec and lindegaard ratio \>3, or aca vasospasm) 4. age ≥18 exclusion criteria: 1. allergy to local anesthetic or contrast 2. coagulation disorders with pt \ 1.4, or ptt \>1.5 times control and/or platelets \<70,000x106/l 3. use of enoxaparin within 12 hours 4. use of clopidogrel within 7 days 5. use of coumadin within 5 days 6. use of ticlopidine within 14 days 7. use of intravenous thrombolytics within 10 days 8. any use of hirudin derivatives during icu stay
shrunken pore syndrome: a retrospective, single center, cohort study

Conditions: Kidney Diseases

Summary: to study the impact a difference in renal clearance of small and large molecules has on long-term survival.

renal dysfunction is considered a major risk factor in cardiac surgery. renal function has earlier been estimated by creatinine and more recently by cystatin c, both of which are analysed in a blood sample. new evidence seems to suggest that if the ratio between estimated renal function from cystatin c and creatinine is below 60% the patient has a higher rate of mortality irrespective of renal function. this syndrome is named shrunken pore syndrome. we study patients whom have undergone elective cardiac surgery at our institution and on whom we before the surgery has collected blood samples. they are all included in our in house patient registry and qulaity database and afterwards we match this data to our national tax registry to get data on mortality. our aim is to evaluate whether shrunken pore syndrome influence mortality following elective cardiac surgery.

Eligibility criteria:
inclusion criteria: * elective cabg and/or savr at the department of cardiothoracic surgery, skåne university hospital in lund, sweden between 1 january 2010 and 31 december 2015. exclusion criteria: * emergency operation * redo operation * preoperatively missing cystatin c or creatinine

Keywords: ckd creatinine cystatin c cardiac surgery gfr
a study of tcr-redirected t cell infusion to prevent hepatocellular carcinoma recurrence post liver transplantation

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma (hcc) recurrence rate is high among liver transplant patients, while treatment measures are limited. this study plans to recruit 39 subjects with hepatitis b virus (hbv) related hcc after liver transplantation. the objective of the study is to assess the safety, tolerability and effectiveness of the hbv specific t cell receptor (hbv/tcr) redirected t cell in the target population.

a open-label, cohort clinical study of t cell receptor-redirected t cells to prevent recurrence of hbv-related hepatocellular carcinoma after liver transplantation. subjects will be enrolled into the observation cohort or treatment cohort. subjects enrolled in the treatment group will receive escalating doses of hbv/ tcr expressing autologous t cells after confirming eligibility. the interval between the first two doses is 14 days, followed by one month of safety monitoring, before subsequent two doses of 1 month interval in between. thereafter, subjects would enter into observation period of the safety and tolerability of the treatment and will be followed up until disease relapse. upon disease recurrence, eligible patient may receive hbv specific t-cell receptor (tcr-t) treatment.

Eligibility criteria:
inclusion criteria: * diagnosis as hepatocellular carcinoma (hcc) * underwent liver transplantation * seropositive for hepatitis b surface antigen (hbsag), or presence of hbv dna or hbv rna before liver transplantation * expression of tcr-t target epitopes within specific human leukocyte antigen (hla) class i profile * no major post-operative complication * life expectancy of at least 3 months * ability to provide informed consent * ability to comply with study procedures exclusion criteria: * known, clinically suspected or has history or central nervous system (cns) and bone metastasis * significant ongoing immunologic rejection based on pathology and clinical diagnosis * evidence or history of significant bleeding diathesis or coagulopathy * prior exposure to any cell therapy such as, but not limited to nk, cik, dc, ctl, stem cells therapy * known history of testing positive for human immunodeficiency virus (hiv) 1 or 2 or known acquired immunodeficiency syndrome (aids) * any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (hiv) infection * women who are pregnant or breast-feeding * any condition that is unstable or which could jeopardise the safety of the patient and his/her compliance in the study

Keywords: hepatocellular carcinoma hepatitis b virus-related post liver transplantation hcc
validation of a handy sleep monitoring device: umindsleep in patients with obstructive sleep apnea

Conditions: Validation

Summary: this is a validation study recruiting subjects with and without obstructive sleep apnea. all subjects will undergo a nocturnal standard polysomnography and umindsleep assessment. sleep parameters, such as sleep stages and apnea umindsleep software. correlation in each parameter between psg and events in polysomnography (psg) will be scored according to the aasm criteria while the sleep parameters will be automatically scored by the umindsleep will be analyzed to determine the magnitude of agreement between umindsleep and psg.

obstructive sleep apnea (osa) is a common sleep disorder in the general population with a prevalence ranging from 4-30%. osa has been shown to be a significant risk factor of many cardiovascular diseases and mental disorders. however, osa is a neglected problem in the general population. in addition, there is a significant unmet need for the treatment of osa. one of the major reason for the under-diagnosis and under-treatment of osa in the general population is a lack of reliable screening tool in detecting osa. in this regard, several devices, such as apnealink, have been developed for the screening of osa. however, as this kind of device only employs time in bed rather than actual sleep time to calculate the apnea index or desaturation index, they tend to underestimate the severity of sleep apnea. in this regard, it is timely need to develop and validate new device that can integrate the actual sleep time and apnea or desaturation events for the precise calculation of sleep apnea index or desaturation index. the umindsleep is a handy and wearable device to acquire eeg, heart rate, saturation, snoring and temperature. the signal will be uploaded to a smartphone through bluetooth. by integrating these signals, the system can automatically analyze several key parameters by the algorithms, such as sleep stages and desaturation events.

Eligibility criteria:
inclusion criteria: * complain of habitual snoring; * ahi as measured by standard psg \> 5/hour exclusion criteria: * aged 17 years old or below * patients with narcolepsy and rem sleep behavior disorder
visual acuity after the combined binocular implantation of +2.5 diopters and +3.0 diopters restor multifocal intraocular lenses.

Conditions: Cataract

Summary: the objective of this study is to assess the visual outcome after the combined binocular implantation of +2.5 d and +3.0 d apodized diffractive multifocal intraocular lenses.

bifocal multifocal intraocular lenses (miol) are effective in achieving good uncorrected visual acuities in the distance and the near. however, the intermediate vision is of increasing relevance for everyday's life. several multifocal intraocular lenses have been developed to improvement intermediate vision. nonetheless, those systems still possess adverse photic effects and do not garantuee spectacle independence. therefore, the combination of a lower-addition bifocal intraocular lense in the distance-dominant eye with a higher-addition bifocal intraocular lense in the fellow-eye might be a promising approach to address these drawbacks of current binocular and trifocal intraocular lenses.

Eligibility criteria:
inclusion criteria: * clinically significant cataract * endothelial cell count: patients aged 18-75 years: \> 1000 cells/mm2; patients \> 75 years: \> 750 cells/mm2 * absence of vision-limiting corneal or retinal comorbidities * capability to understand the informed consent exclusion criteria: * expected postoperative astigmatism \> 0.75 diopters * irregular astigmatism * dilated pupil diameter \< 3 mm * corneal and fundus abnormalities that might cause visual impairments * inability to attend follow-up visits

Keywords: multifocal intraocular lens binocular trifocality cataract surgery spectacle independence intermediate vision photopic vision mesopic vision scotopic vision binocular vision
vulnerability markers in pathological gambling

Conditions: Gaming; Gambling

Summary: addictions without substances are an emergent problem giving rise to a recent and increasing request of care. among these new addictions, pathological gambling and pathological online video gaming which are up. the purpose of this study is to identify vulnerability factors (personality traits, decision making strategies...), which are common or specific to each type of game (on line poker, casino, mmorpg, and no-gamers).


Eligibility criteria:
inclusion criteria: * arm 1: online poker gamblers who don't play another type of gamble/game * arm 2: casino gamblers who don't play another type of gamble/game * arm 3: mmorpg gamers who don't play another type of gamble/game * arm 4: no-gamblers/gamers subjects * step 2 : only right-handled subjects (due to registration of brain activity) exclusion criteria: -

Keywords: online poker casino massively multiplayer online role-playing game (mmorpg) iowa gambling task (igt) high resolution electroencephalography (hr-eeg)
study of rp-6306 with gemcitabine in advanced solid tumors

Conditions: Adult Solid Tumor

Summary: the primary purpose of this study is to assess the safety and tolerability of rp-6306 in combination gemcitabine, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (mtd) of rp-6306 in combination with gemcitabine, identify a recommended phase 2 dose (rp2d) and preferred schedule, examine preliminary pharmacokinetics (pk) and assess anti-tumor activity.

phase 1, multi-center, open-label, dose-escalation study to: * evaluate the safety profile and mtd of rp-6306 with gemcitabine to establish the rp2d and schedule * characterize the pk and pharmacodynamics of rp-6306 with gemcitabine * assess preliminary anti-tumor activity associated with rp-6306 with gemcitabine

Eligibility criteria:
inclusion criteria: * male or female and ≥18 years-of-age at the time of informed consent. * ecog performance status 0 or 1. * locally advanced or metastatic resistant or refractory solid tumors. * submission of available tumor tissue at screening or willingness to have a biopsy performed if safe and feasible. * measurable disease as per recist v1.1. * ability to swallow and retain oral medications. * acceptable hematologic and organ function at screening. * negative pregnancy test (serum) for women of childbearing potential (wocbp) at screening. * resolution of all toxicities of prior therapy or surgical procedures. * life expectancy ≥12 weeks after the start of the treatment exclusion criteria: * chemotherapy or small molecule antineoplastic agent given within 21 days or \<5 half- lives, whichever is shorter, prior to first dose of study drug. * history or current condition, therapy, or laboratory abnormality that might confound the study results or interfere with the patient's participation for the full duration of the study treatment. * patients who are pregnant or breastfeeding. * known sensitivity to any of the ingredients of rp-6306 or gemcitabine. * life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction or other reasons which, in the investigator's opinion, could compromise the participating patient's safety. * major surgery within 4 weeks prior to first dose of rp-6306 and gemcitabine. * uncontrolled, symptomatic brain metastases. * uncontrolled hypertension. * moderate or severe hepatic impairment * psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.